Market Overview:
The global herceptin biosimilar market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of cancer, rising demand for herceptin biosimilars, and growing preference for cost-effective therapies. Based on type, the global herceptin biosimilar market can be segmented into breast cancer, colorectal cancer, leukemia, lymphoma, and other cancers. Breast cancer is expected to account for the largest share of the global herceptin biosimilar market in 2018. This segment is also projected to grow at a high CAGR during the forecast period.
Product Definition:
Herceptin biosimilar is a type of medication that is similar to the original drug, but is not exactly the same. The purpose of using a biosimilar instead of the original drug is to save money.
Breast Cancer:
A herceptin biosimilar is a medicine that is similar to the original Herceptin. It has been approved by the FDA for breast cancer treatment in 2018 and was commercialized in 2019. The growth of this market can be attributed to factors such as increasing incidence rate, rising awareness about treatment alternatives, and availability of better diagnostics tools.
According to Breastcancer.org, 1 out every 8 women are expected to develop invasive breast cancer during their lifetime (40 years).
Colorectal Cancer:
Colorectal cancer (CRC) is one of the most common cancers occurring in the U.S. According to American Cancer Society, it accounted for nearly 23,820 new cases and 9,230 deaths in 2018. It is estimated that 1 out of every 32 women and 1 out of every 31 men are likely to develop CRC at some point in their lives.
Application Insights:
The oncology centers segment held the largest share of revenue in 2017. This is attributed to growing adoption of herceptin biosimilars for treatment of various cancers, such as breast cancer, colorectal cancer, and leukemia. In addition, presence of key players such as OncoGenex and Genentech that are engaged in developing and commercializing herceptin biosimilars for various cancers is expected to drive growth over the forecast period.
The hospital & clinics segment is anticipated to witness significant growth owing to increasing awareness about availability of advanced treatments coupled with rising incidences related diseases across the globe. For instance, according to WHO statistics published in 2018 regarding cancer incidence rates globally; it has been estimated that around 1 in 8 women get diagnosed with invasive breast carcinoma every year while 1 out of 8 men develop prostate cancer during their lifetime respectively.
Regional Analysis:
North America dominated the global herceptin biosimilar market in 2017. This is due to the presence of a large number of biopharmaceutical companies, which are engaged in developing and commercializing biosimilars. In addition, approval and launch events for biosimilars have taken place at a faster pace in this region as compared to other regions. For instance, on 6th September 2016, Pfizer Inc., announced that it received FDA approval for Xofigo (idursulfase beta), its new drug application was approved by FDA on August 11th 2016.
Asia Pacific is expected to be one of the fastest-growing regions over the forecast period owing to increasing healthcare expenditure levels coupled with rising patient awareness levels regarding treatment options available for various diseases such as cancer and leukemia among others.
Growth Factors:
- Increasing incidence of breast cancer: The incidence of breast cancer is increasing at a rapid pace across the globe. This is primarily attributed to changing lifestyle and dietary habits, growing population, and aging population. According to the American Cancer Society, around 252,710 new cases of invasive breast cancer are expected to be diagnosed in women in 2017 in the US alone. This number is projected to rise to 322,600 by 2030. This provides a major growth opportunity for biosimilar manufacturers of Herceptin.
- Growing demand for affordable treatment options: The high cost of branded drugs has been a major concern for healthcare providers and patients alike across the globe. Biosimilars offer an affordable alternative to expensive branded drugs and are likely to gain traction in the market as more and more people become aware about them.
Scope Of The Report
Report Attributes
Report Details
Report Title
Herceptin Biosimilar Market Research Report
By Type
Breast Cancer, Colorectal Cancer, Leukemia, Lymphoma, Other
By Application
Hospital & Clinics, Oncology Centers, Other
By Companies
Amgen, AryoGen Biopharma, Biocon, Celltrion, Gedeon Richter, Genor Biopharma, Mabion, Mylan, Roche, The Instituto Vital Brazil
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
248
Number of Tables & Figures
174
Customization Available
Yes, the report can be customized as per your need.
Global Herceptin Biosimilar Market Report Segments:
The global Herceptin Biosimilar market is segmented on the basis of:
Types
Breast Cancer, Colorectal Cancer, Leukemia, Lymphoma, Other
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital & Clinics, Oncology Centers, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Amgen
- AryoGen Biopharma
- Biocon
- Celltrion
- Gedeon Richter
- Genor Biopharma
- Mabion
- Mylan
- Roche
- The Instituto Vital Brazil
Highlights of The Herceptin Biosimilar Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Breast Cancer
- Colorectal Cancer
- Leukemia
- Lymphoma
- Other
- By Application:
- Hospital & Clinics
- Oncology Centers
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Herceptin Biosimilar Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
A herceptin biosimilar is a medicine that is similar to the original Herceptin drug. It is made by a different company and has the same active ingredients as the original drug.
Some of the key players operating in the herceptin biosimilar market are Amgen, AryoGen Biopharma, Biocon, Celltrion, Gedeon Richter, Genor Biopharma, Mabion, Mylan, Roche, The Instituto Vital Brazil.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Herceptin Biosimilar Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Herceptin Biosimilar Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Herceptin Biosimilar Market - Supply Chain
4.5. Global Herceptin Biosimilar Market Forecast
4.5.1. Herceptin Biosimilar Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Herceptin Biosimilar Market Size (000 Units) and Y-o-Y Growth
4.5.3. Herceptin Biosimilar Market Absolute $ Opportunity
5. Global Herceptin Biosimilar Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Herceptin Biosimilar Market Size and Volume Forecast by Type
5.3.1. Breast Cancer
5.3.2. Colorectal Cancer
5.3.3. Leukemia
5.3.4. Lymphoma
5.3.5. Other
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Herceptin Biosimilar Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Herceptin Biosimilar Market Size and Volume Forecast by Application
6.3.1. Hospital & Clinics
6.3.2. Oncology Centers
6.3.3. Other
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Herceptin Biosimilar Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Herceptin Biosimilar Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Herceptin Biosimilar Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Herceptin Biosimilar Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Herceptin Biosimilar Demand Share Forecast, 2019-2026
9. North America Herceptin Biosimilar Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Herceptin Biosimilar Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Herceptin Biosimilar Market Size and Volume Forecast by Application
9.4.1. Hospital & Clinics
9.4.2. Oncology Centers
9.4.3. Other
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Herceptin Biosimilar Market Size and Volume Forecast by Type
9.7.1. Breast Cancer
9.7.2. Colorectal Cancer
9.7.3. Leukemia
9.7.4. Lymphoma
9.7.5. Other
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Herceptin Biosimilar Demand Share Forecast, 2019-2026
10. Latin America Herceptin Biosimilar Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Herceptin Biosimilar Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Herceptin Biosimilar Market Size and Volume Forecast by Application
10.4.1. Hospital & Clinics
10.4.2. Oncology Centers
10.4.3. Other
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Herceptin Biosimilar Market Size and Volume Forecast by Type
10.7.1. Breast Cancer
10.7.2. Colorectal Cancer
10.7.3. Leukemia
10.7.4. Lymphoma
10.7.5. Other
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Herceptin Biosimilar Demand Share Forecast, 2019-2026
11. Europe Herceptin Biosimilar Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Herceptin Biosimilar Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Herceptin Biosimilar Market Size and Volume Forecast by Application
11.4.1. Hospital & Clinics
11.4.2. Oncology Centers
11.4.3. Other
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Herceptin Biosimilar Market Size and Volume Forecast by Type
11.7.1. Breast Cancer
11.7.2. Colorectal Cancer
11.7.3. Leukemia
11.7.4. Lymphoma
11.7.5. Other
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Herceptin Biosimilar Demand Share, 2019-2026
12. Asia Pacific Herceptin Biosimilar Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Herceptin Biosimilar Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Herceptin Biosimilar Market Size and Volume Forecast by Application
12.4.1. Hospital & Clinics
12.4.2. Oncology Centers
12.4.3. Other
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Herceptin Biosimilar Market Size and Volume Forecast by Type
12.7.1. Breast Cancer
12.7.2. Colorectal Cancer
12.7.3. Leukemia
12.7.4. Lymphoma
12.7.5. Other
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Herceptin Biosimilar Demand Share, 2019-2026
13. Middle East & Africa Herceptin Biosimilar Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Herceptin Biosimilar Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Herceptin Biosimilar Market Size and Volume Forecast by Application
13.4.1. Hospital & Clinics
13.4.2. Oncology Centers
13.4.3. Other
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Herceptin Biosimilar Market Size and Volume Forecast by Type
13.7.1. Breast Cancer
13.7.2. Colorectal Cancer
13.7.3. Leukemia
13.7.4. Lymphoma
13.7.5. Other
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Herceptin Biosimilar Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Herceptin Biosimilar Market: Market Share Analysis
14.2. Herceptin Biosimilar Distributors and Customers
14.3. Herceptin Biosimilar Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Amgen
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. AryoGen Biopharma
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Biocon
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Celltrion
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Gedeon Richter
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Genor Biopharma
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Mabion
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Mylan
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Roche
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. The Instituto Vital Brazil
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
